比美吉珠单抗治疗活动性银屑病关节炎且既往肿瘤坏死因子抑制剂应答不佳患者:III期BE COMPLETE研究及其开放标签扩展BE VITAL的52周安全性与有效性
BE COMPLETE研究16周双盲期结束后,患者进入开放标签扩展BE VITAL,全部接受比美吉珠单抗160 mg每4周一次至第52周。347/400例(86.8%)完成52周;安全性特征与既往报告一致,未发现新安全信号;第16至52周临床与患者报告结局维持疗效。
要点
- 至第52周,≥1次治疗中出现的不良事件暴露调整发生率为126.0/100患者年,严重治疗中出现的不良事件为7.0/100患者年。
- 最常见治疗中出现的不良事件为SARS-CoV-2(COVID-19)、口腔念珠菌病、鼻咽炎和尿路感染;所有真菌感染均为轻或中度且局限。
- 第52周,比美吉珠单抗随机组51.7% vs 安慰剂/比美吉珠单抗组40.6%达到ACR50应答,47.2% vs 33.1%达到最小疾病活动度。
核心结论
- 比美吉珠单抗安全性特征与既往报告一致,未发现新安全信号。
- 第16至52周观察到持续疗效。
研究设计与样本
- 完成16周III期双盲、安慰剂对照BE COMPLETE研究(NCT03896581)的患者进入开放标签扩展BE VITAL(NCT04009499)。
- BE VITAL中全部患者接受比美吉珠单抗160 mg每4周一次,报告至第52周的安全性与有效性。
主要发现
- 347/400例(86.8%)患者完成第52周。
- 至第52周,≥1次治疗中出现的不良事件暴露调整发生率为126.0/100患者年,严重治疗中出现的不良事件为7.0/100患者年。
- 最常见治疗中出现的不良事件为SARS-CoV-2(COVID-19)、口腔念珠菌病、鼻咽炎和尿路感染。
- 所有真菌感染均为轻或中度且局限;2例患者因口腔念珠菌病中断研究。
- 未报告活动性结核、葡萄膜炎或炎症性肠病病例;发生1例猝死。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess 52-week safety and efficacy of bimekizumab in patients with active psoriatic arthritis (PsA) and prior inadequate response/intolerance to tumour necrosis factor inhibitors. METHODS: Patients completing the 16-week phase III double-blind, placebo-controlled BE COMPLETE (NCT03896581) study entered the open-label extension, BE VITAL (NCT04009499). All patients in BE VITAL received 160 mg bimekizumab every 4 weeks. Safety and efficacy are reported to week 52. RESULTS: A total of 347/400 (86.8%) patients completed week 52. To week 52, the exposure-adjusted incidence rate/100 patient-years for ≥1 treatment-emergent adverse event (TEAE) was 126.0, and was 7.0 for serious TEAEs. The most frequent TEAEs were SARS-CoV-2 (COVID-19), oral candidiasis, nasopharyngitis and urinary tract infection. All fungal infections were mild or moderate in severity and localised; two patients discontinued the study due to oral candidiasis. No cases of active tuberculosis, uveitis or inflammatory bowel disease were reported. One sudden death occurred. Sustained efficacy was observed with bimekizumab from week 16 to 52 across clinical and patient-reported outcomes. At week 52, 51.7% bimekizumab-randomised and 40.6% placebo/bimekizumab patients (receiving bimekizumab from week 16 to 52) had ≥50% improvement in the American College of Rheumatology criteria. Complete skin clearance (Psoriasis Area and Severity Index 100) was achieved by 65.9% bimekizumab and 60.2% placebo/bimekizumab patients at week 52. Minimal disease activity was achieved by 47.2% bimekizumab and 33.1% placebo/bimekizumab patients at week 52. CONCLUSIONS: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from week 16 to 52.
引用
- Coates LC, Landewé R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024. PMID: 38388171. doi:10.1136/rmdopen-2023-003855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。